Min Lu

Prior to joining Kirkland & Ellis, Min represented clients in the following selected transactions:

• A leading food delivery business operating on the transfer of all of the issued shares to an affiliate of the largest e-commerce company in China for US$9.5 billion;
• One of the world largest communications group in its GBP 39 million sale of 100% equity interest of its subsidiary in China;
• Buyer consortium led by a Greater China healthcare-focused investment management group in its US$ 607 million acquisition of a NASDAQ-listed pharmaceutical corporation;
• A Chinese state-owned oil and gas enterprise in its US$3.25 billion senior notes offering;
• A multinational communications and information technology company in setting up a joint venture with a Chinese industrial investment company;
• A Singapore sovereign wealth fund in its US$50 million investment in a Chinese electronics company;
• A global alternative investments firm, in its equity financing for the US$1.1 billion acquisition of an American-based global marketing information services company;
• A Shanghai Stock Exchange-listed company in its US$263 million acquisition of majority stake in a leading tech-focused e-retailer in North America;
• A Shanghai Stock Exchange-listed company in its US$300 million acquisition of a British video game developer and publisher;
• A Chinese online dating service company in its US$250 million acquisition of a NASDAQ-listed company;
• A China-based fund, as equity sponsor, in the privatization of a NASDAQ-listed company, which is principally engaged in design, manufacture, and distribution of cast resin transformers;
• The Special Committee of a NASDAQ-listed company, which is principally engaged in multi-channel retail business in China, in its going-private transaction;
• Seller consortium consisting of multiple private equity funds in the RMB10 billion disposition of the shares in an economy hotel chain;
• A Singapore sovereign wealth fund in its US$4.8 million investment in a Hong Kong-based investment holding company principally engaged in the manufacture and sales of medical products;
• The Special Committee of a NASDAQ-listed company, which is a global mobile app and platform development firm, in its going-private transaction;
• A leading provider of private educational services in China, invested by one of the leading private equity investors in Asia Pacific, in its recapitalization;
• Multiple underwriters in the US$315 million SEC-registered follow-on primary/secondary equity offering of one of the largest manufacturers of plasma products in China; and
• One of the leading private equity investors in Asia Pacific, as equity sponsor in the privatization of a developer of natural gas distribution systems in China.